The following chart illustrates the various bottlenecks restraining the development of France’s pharmaceutical industry, including lack of investment, fewer new molecules than other European countries, disappointing performance in biological drugs, and long waiting times for drug approval.
France spends 11.6% of its GDP on health. This is behind the USA (17.1%) but ahead of Germany (11.2%), Japan…
Top 20 Pharma Companies in France The following chart shows the top 20 pharma companies in France, ranked by sales…
This map shows the overall contribution of the pharmaceutical industry to the French economy, including number of…
The following chart shows the top 20 pharma companies in France, ranked by sales for the year 2015. Global giant…
In France, the ACOSS (central agency of social security funds) is in charge of the social security general…
The latest news from Russian pharma, including Biocad’s ramping up of Sputnik V COVID-19 vaccine manufacturing,…
After an illustrious career in oncology R&D, contributing greatly to the development of cutting-edge cancer…
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…